In a significant development within Pakistan’s pharmaceutical sector, Citi Pharma Limited (CPHL) has announced its foray into the veterinary healthcare market through its wholly owned subsidiary, Citi Veterinary Limited (CVL). This strategic move not only diversifies Citi Pharma’s portfolio but also signals a growing recognition of the importance of animal health in the country.
Entering pet care
On September 12, 2025, Citi Pharma disclosed to the Pakistan Stock Exchange that CVL has commenced operations, launching an initial lineup of 32 veterinary products, including vaccines. The company has already established Letters of Credit (LCs) for eight of these products to ensure timely availability and supply. For the fiscal year 2025-26, CVL projects a turnover of approximately PKR 1.5 billion, with a gross profit margin of 13%. Looking ahead, the company aims to scale operations and achieve a turnover target of PKR 10 billion within the next three years. The content in this publication is expensive to produce. But unlike other journalistic outfits, business publications have to cover the very organizations that directly give them advertisements. Hence, this large source of revenue, which is the lifeblood of other media houses, is severely compromised on account of Profit’s no-compromise policy when it comes to our reporting. No wonder, Profit has lost multiple ad deals, worth tens of millions of rupees, due to stories that held big businesses to account. Hence, for our work to continue unfettered, it must be supported by discerning readers who know the value of quality business journalism, not just for the economy but for the society as a whole.To read the full article, subscribe and support independent business journalism in Pakistan
